MUTATIONS IN BRCA2

• A. Act as protective genes in reducing the risk of developing prostate cancer
• B. Are irrelevant in prostate cancer
• C. Increase the risk of developing prostate cancer ✓
• D. Cause the prostate gland to shrink

BRCA2 is a tumor suppressor gene that plays a crucial role in repairing damaged DNA. Mutations in this gene can lead to an increased risk of various cancers, including prostate cancer. Studies have shown that individuals with mutations in BRCA2 are more likely to develop aggressive forms of prostate cancer at a younger age compared to those without these mutations. Therefore, it is evident that mutations in BRCA2 do not act as protective genes but instead elevate the risk of developing prostate cancer.

In other words, the presence of BRCA2 mutations has been associated with an increased risk for various cancers, including breast, ovarian, and prostate cancer. Specifically, BRCA2 mutations have been linked to an elevated risk of early-onset prostate cancer in males younger than 65. Individuals with BRCA2 mutations are more likely to develop an advanced stage of prostate cancer, leading to shorter survival times. These mutations are not protective but rather confer a higher susceptibility to developing prostate cancer.